Onyx Files Carfilzomib For Accelerated Approval With Two Phase III Trials Ongoing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With two Phase III trials already in progress, Onyx Pharmaceuticals Inc. looks well-positioned for an FDA accelerated approval of its proteasome inhibitor carfilzomib in relapsed and refractory multiple myeloma – and if accelerated approval is not granted, it should have data to resubmit roughly a year later.
You may also be interested in...
Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
It appears the burden of serious adverse events was too much to justify the 1.8 month survival benefit conferred by the addition of Millennium’s Velcade (bortezomib) to Roche’s Rituxan (rituximab) in patients with relapsed follicular lymphoma.
Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
It appears the burden of serious adverse events was too much to justify the 1.8 month survival benefit conferred by the addition of Millennium’s Velcade (bortezomib) to Roche’s Rituxan (rituximab) in patients with relapsed follicular lymphoma.
Adcetris Review Adds Some Clarity To Principles For Accelerated Approval
Sponsors seeking insight into when a single-arm trial will be deemed acceptable support for accelerated approval by FDA and its Oncologic Drugs Advisory Committee can look to the recent review of Seattle Genetics’ Adcetris (brentuximab) for clues.